Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the target of some unusual options trading on Thursday. Investors acquired 23,699 call options on the company. This is an increase ...

Barry Stein had ignored symptoms that started appearing in 1995. Now he's committed to helping people recognize the signs of ...

Chicago Partners Investment Group LLC decreased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 35.7% during the 4th quarter, Holdings Channel.com reports. The ...

The NHS doesn’t offer bowel screening until we’re 50. Yet with cancer rates rising, it may be worth forking out for a private test ...

Biodexa Strengthens Management TeamAppointment of Dr Gary A. Shangold as Chief Medical OfficerBiodexa Pharmaceuticals PLC ...

Hereditary cancer risk can be passed down among generations, just like physical characteristics that we can identify in our ...

Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023. Refining colorectal cancer screening strategies using polygenic risk scores and classical risk ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

If conditions such as familial adenomatous polyposis, MYH-associated polyposis, or hereditary non-polyposis colorectal cancer run in your family, that raises the risk for colon cancer (and other ...

"Small intestinal tumors are much rarer than those in the colon, but the risk is higher in cases of familial adenomatous polyposis," said lead researcher Hiroshi Ohno, from RIKEN IMS, in a statement.

Emily King of Mobile, Alabama, was diagnosed with colon cancer five years ago at the age of 27. She had experienced some diarrhea, abdominal pain and anemia, but having cancer had never entered ...